House Journal: Page 937: Wednesday, April 2, 2003
Page 3
1 reimbursement of expenses in connection with bona fide
2 clinical trials. As used in this paragraph, "clinical
3 trial" means an approved clinical trial conducted in
4 connection with a research study designed to answer
5 specific questions about vaccines, new therapies, or
6 new ways of utilizing known treatments.
7 c. Any gift, fee, payment, subsidy, or other
8 economic benefit the value of which is less than
9 twenty-five dollars.
10 d. A scholarship or other support for medical
11 students, residents, or fellows to attend a
12 significant educational, scientific, or policymaking
13 conference of a national, regional, or specialty
14 medical or other professional association if the
15 recipient of the scholarship or other support is
16 selected by the association.
17 3. a. Annually on or before January 1, every
18 pharmaceutical manufacturing company shall disclose to
19 the board the value, nature, and purpose of any gift,
20 fee, payment, subsidy, or other economic benefit
21 provided in connection with detailing, promotional, or
22 other marketing activities by the company, directly or
23 through its pharmaceutical marketers, to any
24 practitioner, hospital, health care facility,
25 pharmacist, health benefit plan administrator, or any
26 other person in this state authorized to prescribe,
27 dispense, distribute, or purchase prescription drugs
28 in this state. Disclosure shall be made on a form and
29 in a manner prescribed by the board and shall be made
30 for the period beginning July 1 and ending June 30 of
31 the previous state fiscal year. An initial disclosure
32 shall be made on January 15, 2004, for the period
33 beginning July 1, 2003, and ending December 31, 2003.
34 The board shall provide to the office of the attorney
35 general complete access to the information required to
36 be disclosed under this subsection. The office of the
37 attorney general shall report annually on the
38 disclosures made under this section to the governor
39 and the general assembly on or before March 1.
40 b. Each company subject to the provisions of this
41 section shall also disclose to the board, on or before
42 January 1, 2004, and annually thereafter, the name and
43 address of the individual responsible for the
44 company's compliance with this section.
45 c. The board and the office of the attorney
46 general shall keep confidential all trade secrets as
47 defined in section 550.2. The disclosure form
48 prescribed by the board shall permit the company to
49 identify any information that is a trade secret.
50 d. The company is exempt from disclosure of any
© 2003 Cornell College and
League of Women Voters of Iowa
Comments about this site or page?
hjourn@legis.iowa.gov.
Please remember that the person listed above does not vote on bills. Direct all comments concerning legislation to State Legislators.
Last update: Thu Aug 7 12:20:00 CDT 2003
URL: /DOCS/GA/80GA/Session.1/HJournal/00900/00937.html
jhf